JOURNAL ARTICLE

A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [(14)C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [(13)C6]-labeled basimglurant in humans

Elena Guerini, Simone Schadt, Gerard Greig, Ruth Haas, Christophe Husser, Manfred Zell, Christoph Funk, Thomas Hartung, Andreas Gloge, Navita L Mallalieu
Xenobiotica; the Fate of Foreign Compounds in Biological Systems 2017, 47 (2): 144-153
27123695
1. The emerging technique of employing intravenous microdose administration of an isotope tracer concomitantly with an [(14)C]-labeled oral dose was used to characterize the disposition and absolute bioavailability of a novel metabotropic glutamate 5 (mGlu5) receptor antagonist under clinical development for major depressive disorder (MDD). 2. Six healthy volunteers received a single 1 mg [(12)C/(14)C]-basimglurant (2.22 MBq) oral dose and a concomitant i.v. tracer dose of 100 μg of [(13)C6]-basimglurant. Concentrations of [(12)C]-basimglurant and the stable isotope [(13)C6]-basimglurant were determined in plasma by a specific LC/MS-MS method. Total [(14)C] radioactivity was determined in whole blood, plasma, urine and feces by liquid scintillation counting. Metabolic profiling was conducted in plasma, urine, blood cell pellet and feces samples. 3. The mean absolute bioavailability after oral administration (F) of basimglurant was ∼67% (range 45.7-77.7%). The major route of [(14)C]-radioactivity excretion, primarily in form of metabolites, was in urine (mean recovery 73.4%), with the remainder excreted in feces (mean recovery 26.5%). The median tmax for [(12)C]-basimglurant after the oral administration was 0.71 h (range 0.58-1.00) and the mean terminal half-life was 77.2 ± 38.5 h. Terminal half-life for the [(14)C]-basimglurant was 178 h indicating presence of metabolites with a longer terminal half-life. Five metabolites were identified with M1-Glucuronide as major and the others in trace amounts. There was minimal binding of drug to RBCs. IV pharmacokinetics was characterized with a mean ± SD CL of 11.8 ± 7.4 mL/h and a Vss of 677 ± 229 L. 4. The double-tracer technique used in this study allowed to simultaneously characterize the absolute bioavailability and disposition characteristics of the new oral molecular entity in a single study.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
27123695
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"